Standing Order
AstraZeneca PLC

Dashboard

AstraZeneca PLC

AZNNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$270B
Price$174.3552w $68.72 – $209.48
Conviction4/ 5
Revenue (TTM)$62.2B
Revenue growth YoY+7.0%
P/E (trailing)24.6
Gross margin80.1%
Operating margin23.7%
Net margin17.7%
52w price change+138.8%
Next earnings—

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 16
    RegulatorySEC

    AstraZeneca's Klygefa (gefurulimab) approved in the EU.

  • Nov 16
    RegulatorySEC

    AstraZeneca's Imfinzi + EV approved in US for bladder cancer

  • Nov 16
    RegulatorySEC

    AstraZeneca's Klygefa (gefurulimab) approved in the US

  • Nov 16
    RegulatorySEC

    6-K: Baxfendy recommended for approval in the EU

  • Nov 10
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Nov 2
    Securities offeringSEC

    AstraZeneca 6-K reports admission of further securities to trading.

  • Nov 2
    OtherSEC

    AstraZeneca 6-K discloses total voting rights.

  • Oct 30
    Financial resultsSEC

    AstraZeneca PLC files 6-K disclosing third quarter results.

  • Oct 27
    RegulatorySEC

    ENHERTU approved in EU for HER2-positive early breast cancer (EBC).

  • Oct 22
    RegulatorySEC

    Ultomiris approved in the US for IgA nephropathy per 6-K filing.

  • Oct 8
    Ownership changeSEC

    SEC Form 4 insider transaction filing reported for AZN.

  • Oct 5
    DealSEC

    AstraZeneca completes equity investment in Summit per 6-K filing.

  • Oct 2
    PartnershipSEC

    AstraZeneca and Daiichi Sankyo collaboration with Summit for Datroway.

  • Oct 1
    Securities offeringSEC

    AstraZeneca 6-K reports admission of further securities to trading.

  • Oct 1
    OtherSEC

    AstraZeneca 6-K discloses total voting rights as of filing date.

  • Sep 29
    DealSEC

    AstraZeneca announces equity investment in Summit via 6-K filing.

  • Sep 23
    RegulatorySEC

    Trixeo approved in EU for asthma per 6-K filing.

  • Sep 21
    RegulatorySEC

    Klygefa recommended for EU approval by CHMP

  • Sep 21
    RegulatorySEC

    ENHERTU recommended for approval in EU for early breast cancer

  • Sep 18
    Ownership changeSEC

    6-K reports director/PDMR shareholding notification for AstraZeneca.

Not financial advice — research and opinion only. Disclosures